Protagonist Therapeutics (PTGX) Enterprise Value (2017 - 2025)
Historic Enterprise Value for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$576.1 million.
- Protagonist Therapeutics' Enterprise Value fell 2291.26% to -$576.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$576.1 million, marking a year-over-year decrease of 2291.26%. This contributed to the annual value of -$418.9 million for FY2024, which is 2263.35% down from last year.
- Per Protagonist Therapeutics' latest filing, its Enterprise Value stood at -$576.1 million for Q3 2025, which was down 2291.26% from -$570.5 million recorded in Q2 2025.
- In the past 5 years, Protagonist Therapeutics' Enterprise Value ranged from a high of -$192.6 million in Q2 2021 and a low of -$576.1 million during Q3 2025
- Over the past 5 years, Protagonist Therapeutics' median Enterprise Value value was -$320.8 million (recorded in 2023), while the average stood at -$363.8 million.
- As far as peak fluctuations go, Protagonist Therapeutics' Enterprise Value plummeted by 35413.03% in 2021, and later surged by 2739.22% in 2022.
- Over the past 5 years, Protagonist Therapeutics' Enterprise Value (Quarter) stood at -$326.9 million in 2021, then increased by 27.39% to -$237.4 million in 2022, then crashed by 43.93% to -$341.6 million in 2023, then decreased by 22.63% to -$418.9 million in 2024, then crashed by 37.51% to -$576.1 million in 2025.
- Its last three reported values are -$576.1 million in Q3 2025, -$570.5 million for Q2 2025, and -$574.4 million during Q1 2025.